Arnon P. Kater, MD, PhD, on Treatment Advantages With Ibrutinib Plus Venetoclax for Older Patients With CLL

Posted: Wednesday, July 7, 2021

Arnon P. Kater, MD, PhD, of the University of Amsterdam, discusses the clinical implications of findings from the phase III GLOW study, which suggests that fixed-duration ibrutinib and venetoclax, for previously untreated older patients with chronic lymphocytic leukemia, improves progression-free survival, and offers depth and duration of remission, as well as extended time to next treatment.